2023 · ARCHIVES OF CARDIOVASCULAR DISEASES

Transcatheter aortic valve implantation using the SAPIEN 3 valve to treat aortic regurgitation: The French multicentre S3AR study

Delhomme, Clemence, Urena, Marina, Zouaghi, Oualid, Campelo-Parada, Francisco, Ohlmann, Patrick, Rioufol, Gilles, Van Belle, Eric, Pinaud, Frederic, Meneveau, Nicolas, Staat, Patrick, Morel, Olivier, Derimay, Francois, Vincent, Flavien, Rouleau, Frederic, Brochet, Eric, Chong-Nguyen, Caroline, Himbert, Dominique

Journal
ARCHIVES OF CARDIOVASCULAR DISEASES
Année
2023
Volume
116
Numéro
2
Pages
98-105
Mois
FEB
DOI
10.1016/j.acvd.2022.12.003

Abstract

Background: Transcatheter aortic valve implantation now has a major role in the treatment of patients with severe aortic stenosis. However, evidence is scarce on its feasibility and safety to treat patients with pure aortic regurgitation.Aims: We sought to evaluate the results of transcatheter aortic valve implantation using the balloon-expandable SAPIEN 3 transcatheter heart valve (Edwards Lifesciences, Irvine, CA, USA) in patients with pure aortic regurgitation on native non-calcified valves.Methods: We conducted a retrospective and prospective French multicentre observational study. We included all patients with symptomatic severe pure aortic regurgitation on native non-calcified valves, contraindicated to or at high risk for surgical valve replacement, who underwent transcatheter aortic valve implantation using the SAPIEN 3 transcatheter heart valve.Results: A total of 37 patients (male sex, 73%) with a median age of 81 years (interquartile range 69-85 years) were screened using transthoracic echocardiography and computed tomography and were included at eight French centres. At baseline, 83.8% of patients (n = 31) had dyspnoea New York Heart Association class > III. The device success rate was 94.6% (n = 35). At 30 days, the all-cause mortality rate was 8.1% (n = 3) and valve migration occurred in 10.8% of cases (n = 4). Dyspnoea New York Heart Associ-ation class <= II was seen in 86.5% of patients (n = 32), and all survivors had aortic regurgitation grade <= 1. At 1-year follow-up, all-cause mortality was 16.2% (n = 6), 89.7% (n = 26/29) of survivors were in New York Heart Association class <= II and all had aortic regurgitation grade <= 2.Conclusion: Transcatheter aortic valve implantation using the SAPIEN 3 transcatheter heart valve seems promising to treat selected high-risk patients with pure aortic regurgitation on non-calcified native valves, contraindicated to surgical aortic valve replacement.(c) 2023 Elsevier Masson SAS. All rights reserved.

Lire l'article complet